Drug Sales To Soar In Pharmerging Markets On Locally Made Generics, While Biologics Face Hurdles – IMS
This article was originally published in PharmAsia News
Executive Summary
The global use of medicines in the next five years will see the pace of sales in most emerging markets far outstrip developed countries driven by locally made generics under national health care programs. Biologics and biosimilars access remains an issue for many patients in what IMS calls pharmerging markets.